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Abstract
The overall purpose of this LDRD is multifold.  First, we are interested in preparing
new homogeneous catalysts that can be used in the oligomerization of ethylene and in
understanding commercially important systems better.  Second, we are interested in
attempting to support these new homogeneous catalysts in the pores of nano- or mesoporous
materials in order to force new and unusual distributions of a-olefins to be formed during the
oligomerization.  Thus the overall purpose is to try to prepare new catalytic species and to
possibly control the active site architecture in order to yield certain desired products during a
catalytic reaction, much like nature does with enzymes.
In order to rationally synthesize catalysts it is imperative to comprehend the function
of the various components of the catalyst.  In heterogeneous systems, it is of utmost
importance to know how a support interacts with the active site of the catalyst.  In fact, in the
catalysis world this lack of fundamental understanding of the relationship between active site
and support is the single largest reason catalysis is considered an “empirical” or “black box”
science rather than a well-understood one. In this work we will be preparing novel ethylene
oligomerization catalysts, which are normally P-O chelated homogeneous complexes, with
new ligands that replace P with a stable carbene.  We will also examine a commercially
catalyst system and investigate the active site in it via X-ray crystallography.  We will also
attempt to support these materials inside the pores of nano- and mesoporous materials.
Essentially, we will be tailoring the size and scale of the catalyst active site and its
surrounding environment to match the size of the molecular product(s) we wish to make.
The overall purpose of the study will be to prepare new homogeneous catalysts, and if
successful in supporting them to examine the effects that steric constraints and pore
structures can have on growing oligomer chains.
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6General Introduction
The overall purpose of this LDRD is multifold.  First, we are interested in preparing
new homogeneous catalysts that can be used in the oligomerization of ethylene and in
understanding commercially important systems better.  Secondly, our interest resides in
supporting these new homogeneous catalysts in the pores of nano- or mesoporous materials
in order to force new and unusual distributions of a-olefins to be formed during the
oligomerization.  Thus the overall purpose is to try to control the active site architecture in
order to yield certain desired products during a catalytic reaction, much like nature does with
enzymes.
Described in this report is chemistry involved primarily with the first aspect of the
proposed research – the synthesis of new coordinating ligands.  We were interested in
preparing variations upon the SHOP catalyst system used in the oligomerization of ethylene
by Shell Chemical Company.  A key feature of the SHOP ligand used with the Ni(2+) metal
ion to afford an active catalyst is the chelating  nature of the phosphine/carboxylate portions
of the ligand, as shown by arrows (Figure 1).  It is believed that this ligand chelates to nickel
during catalyst formation, and in the presence of a reducing agent such as borohydride, the
formation of a ligated nickel hydride is the active species.  Ethylene can then react with the
Ni-H, form an alkyl group via insertion chemistry, and generate an empty orbital upon
insertion.  Repeated coordination of ethylene followed by insertion steps affords longer and
longer chain alkyls.  Eventually, the alkyl group undergoes so-called b-H elimination rather
than insertion, and the resulting a-olefin desorbs from the catalyst.  This is the traditional
view of the catalytic cycle involving olefin oligomerization.
Over the past decade stable carbenes have been shown to function as adequate, or in
some cases improved, replacements for phosphines in catalytic applications.  We were
interested in preparing new ligands based on modifications to these stable carbenes – an
important feature would be to attach a arm to the carbene that has an atom that can chelate to
the active metal.  This would lead to homogeneous catalysts of Ni, Rh, or Pd containing these
chelating ligands.  We were also interested in potentially attaching these homogeneous
ligands to solid supports, and the preparation of a tethered chelating carbene ligand is
described.
C
O
O
P
Metal
Figure 1.  Chelating Nature of SHOP-type Ligand.
7Ni-Based Complexes with Carbene Ligands
Introduction
Since the isolation of the first N-heterocyclic carbene (NHC) in 1991, there has been
much research into NHC complexes and their applications in catalysis.1-3 Recently there has
been interest in NHCs functionalized with additional donor groups, which can potentially
form chelating NHC ligands. NHC ligands have been used in catalysts in place of phosphines
and in many cases shown superior catalytic properties, due to their better s-donor abilities,
for example in olefin metathesis catalysis.4 We were interested in preparing chelating nickel
complexes of functionalized carbene ligands, which would be analogous to the P–O chelate
Ni complexes used as catalysts for the oligomerization of ethylene to a-olefins in the Shell
Higher Olefins Process (SHOP).
A difficulty in the synthesis of functionalized imidazole based NHC complexes is the
formation of the carbene itself. The standard procedure, involving deprotonation of an
imidazolium precursor using a strong base, often fails because the additional functional
group can possess acidic protons or be otherwise reactive under such conditions. Alternative
methods to synthesize functionalized carbene complexes have included (i) formation of an
Ag carbene complex, followed by transmetallation, (ii) oxidative addition of imidazolium
C–H bonds to a low-valent metal center, and (iii) reaction of an imidazolium salt with a
metal complex containing a basic ligand. We have prepared functionalized Ni carbene
complexes by method (iii). In this case, the carbene is generated in situ through
deprotonation by the basic ligand, which is in turn replaced by the carbene. In nickel
chemistry, precedence for this type of reaction comes from the work of Cowley et al., in
which nickelocene was treated with an imidazolium chloride, leading to displacement of one
of the cyclopentadienyl rings and deprotonation of the imidazolium to give a
CpNi(carbene)Cl species.5
Discussion
Synthesis of Ligands
Imidazolium salts functionalized with N- and O-donors were prepared by known
procedures. Pyridine functionalized imidazolium bromides, Im(R, 2-Py), have been
synthesized by heating a neat mixture of an N-alkylimidazole and 2-bromopyridine.6-9 This
reaction appears to be quite complex. Others have reported that the reaction also generates
dipyridylimidazolium salts10, and we have seen evidence for the formation of
dialkylimidazolium species as well. Nevertheless, reasonable yields of the desired species
can be obtained. Cavell has reported syntheses of carbonyl functionalized imidazolium salts
by treatment of N-methylimidazole with an a-bromo ester or ketone.11 These reactions
generally proceed readily in THF at room temperature. Using this method, we prepared an
analogous imidazolium ketone, derived from N-n-butylimidazole, rather than N-
methylimidazole, in order to aid solubility of metal complexes.
8We were also interested in preparing a ligand containing a tether that might allow a
carbene complex to be attached to a support such as silica.12 It was attempted to prepare an
imidazolium salt functionalized with pyridine, and 3-propyltriethoxysilane. No reaction was
observed, however, between N-(2-pyridyl)imidazole and (3-chloropropyl)triethoxysilane,
even in refluxing 1,4-dioxane. It was necessary to convert the chloropropylsilane to the
analogous iodo species, by treatment with NaI in refluxing acetone, to allow the
functionalized imidazolium [Im(2-Py,(CH2)3Si(OEt)3]+I– to be prepared (Scheme 1). This
moiety could potentially be grafted onto silica through reaction of the triethoxysilyl group
with Si–OH groups on the silica, with elimination of ethanol and formation of Si–O–Si
linkages.
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Synthesis of Nickel Carbene Complexes
It was first attempted to prepare cyclopentadienyl carbene complexes by treatment of
functionalized imidazolium salts with nickelocene, analogous to the previous work5.
Reaction of Cp2Ni with the pyridyl functionalized imidazolium bromide, [Im(Bu,2-Py)]+Br–,
in refluxing THF gave a green compound, which was isolated as its BF4– salt by treatment
with AgBF4 (Scheme 2). The 1H-NMR spectrum of this species showed a singlet due to a Cp
ring and peaks consistent with a pyridyl carbene ligand. In particular, the distinctive peak at
ca. d 11 in CDCl3 of the imidazolium precursor due to the C2-bound proton is no longer
present, suggesting deprotonation had occurred. X-ray crystallography (Figure 2, page 18)
confirmed the structure to consist of an 18 electron CpNi(carbene) cation, {CpNi-h2-[Im(Bu,
2-Py)]}+, featuring a bidentate pyridine-carbene ligand. The Ni–C bond length of 1.861(2) Å
is somewhat shorter than that in CpNi[Im(Mes2)]Cl (1.917(9) Å)5, presumably due to the
cationic nickel center and the lack of sterically demanding mesityl groups. There is
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a significant difference between the two structures, however, which is that in the chelating
complex described here, the planar carbene group is essentially perpendicular to the Cp ring,
whereas in the monodentate carbene complex, the ring is tilted.  The structure of the bromide
analogue was not determined crystallographically, but in view of the fact that it has a very
similar color and 1H-NMR spectrum as the BF4– salt, it is believed to exist as a similar salt
with an h2 carbene ligand, rather than a neutral species with the Br coordinated to the metal.
The complex {CpNi-h2-[Im(Bu, 2-Py)]}+BF4– could also be prepared by first forming the
BF4– salt of the imidazolium precursor, followed by reaction with nickelocene (Scheme 2).
Treatment of Cp2Ni with the ketone substituted imidazolium, Im[Bu, CH2COPh]+Br-,
gave a red complex, which was significantly more soluble in organic solvents than the
pyridyl analogue (Scheme 3). X-ray crystallography (Figure 3, page 19) revealed the product
to be a neutral species, with the Ni coordinated by Cp, monodentate carbene and bromide
ligands, CpNi[Im(Bu, CH2COPh)]Br. Unlike with the pyridyl functionalized ligand, the
ketone donor group does not coordinate to the metal. This is demonstrated by a lack of a
short Ni•••O separation, as well as by the IR data, which shows little difference in C–O
stretching frequency between the imidazolium salt (1687 cm–1) and the carbene complex
N N
Ph
n-Bu
+ 
Br–H
O
Nn-Bu
Ni
Br
+ Cp2Ni N
Ph
O
Scheme 3
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(1699 cm–1). Attempts to abstract the bromide to give a cationic species, using AgBF4 in
CH3CN, gave a green oil with nC=O =  1701 cm-1, again suggesting the carbonyl is still not
bound to the metal. In the 1H NMR spectrum of CpNi[Im(Bu, CH2COPh)]Br, the protons of
the CH2 group a to the carbonyl are inequivalent, appearing as a pair of doublets with a
separation by 1.2 ppm. The N-bound CH2 protons of the n-butyl group are also slightly
inequivalent. This suggests that, at room temperature, rotation of the carbene ligand around
the Ni–C bond is hindered.
The above complexes, containing Cp ligands, are all 18 electron compounds. It was
desired to prepare electronically unsaturated carbene complexes, which might be more
effective as catalysts. It was attempted to deprotonate imidazolium salts with Ni(acac)2.
Catalysts have been previously prepared in situ from imidazolium salts and Ni(acac)213-16 but
apparently products of this reaction have not been isolated. Treatment of the pyridyl
substituted imidazolium salt also containing either an n-butyl group, or the
3-propyl(triethoxysilane) group gave a yellow species, whose NMR was consistent with a
(carbene)Ni(acac) species (Scheme 4). No evidence for the bis(carbene) species derived from
protonation of both acac ligands was observed. The ketone functionalized imidazolium salt,
Im[Bu, CH2COPh]+Br-, did not react with Ni(acac)2, suggesting that coordination of the
pyridine is necessary prior to deprotonation to form the carbene complex. The structure of
the silane-substituted species was determined by X-ray crystallography (Figure 4, page 19),
revealing it to consist of a 16 electron cation featuring chelating carbene and acac ligands,
with an iodide counterion. The nickel has a square planar geometry. The Ni–C and Ni–N
bond lengths to the pyridylcarbene ligand (1.864(4) Å and 1.923(3) Å respectively) are very
similar to those of the Cp substituted analogue. The acac ligand is bound essentially
symmetrically to the nickel. This complex appears to be the first example of a structurally
characterized transition metal complex containing both an NHC and an acac ligand.17
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Experimental
Experimental Details
Reactions were performed under an inert atmosphere of Ar, using Schlenk or drybox
techniques, except where otherwise noted. Im(Bu, 2-Py)+Br–.H2O8, (EtO)3Si(CH2)3I18, and N-
(2-pyridyl)imidazole19 were synthesized as described previously. NMR spectra were recorded
11
on Bruker AC250 and Bruker Avance 500 spectrometers. Chemical shifts (d) are reported in
ppm relative to TMS (d = 0) and are referenced relative to the residual protio solvent peak
(1H) or a 13C resonance of the solvent. Coupling constants are reported in Hz.
Synthesis of {CpNi[Im(n-Bu, 2-Py)]}+ BF4–
0.22 g AgBF4 (1.1 mmol) was added to a solution of 0.32 g Im(n-Bu, 2-Py)+Br–.H2O
(1.1 mmol) in CH2Cl2 (ca. 10 mL). The resulting white suspension was stirred for 1 h, and
then filtered. The solid residue was extracted with additional CH2Cl2  (ca. 10 mL). The
filtrates were combined and the solvent removed under vacuum to give a brown oil of Im(n-
Bu, 2-Py)+BF4–. 0.21 g Cp2Ni (1.1 mmol) and THF (20 mL) were added, and the resulting
green suspension heated at 100 °C overnight in a thick-walled glass ampoule fitted with a
Teflon stopper. After heating, a light green precipitate had formed, which was isolated by
filtration and dried under vacuum, to give 0.18 g green solid. The filtrate was stored in the
freezer at –20 °C, affording additional product (0.05 g, total yield 52 %). Crystals suitable for
X-ray diffraction studies were obtained by layering diethyl ether onto a CH2Cl2 solution.
Analysis calcd. for C17H20N3BF4Ni: C, 49.6 %; H, 4.9 %; N, 10.2 %. Found: C, 49.4 %; H,
4.8 %; N, 10.3 %. NMR data: 1H (acetone-d6): 0.98 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3), 1.45
(sextet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 1.87 (quintet, JH–H = 7, 2 H, NCH2CH2CH2CH3),
4.11 (t, JH–H = 7, 2 H, NCH2CH2CH2CH3), 5.91 (s, 5 H, C5H5), 7.30 (t, JH–H = 6, 1 H, C5H4N),
7.60 (d, JH–H = 2, 1 H, carbene CH), 8.2 (m, 2 H, C5H4N) 8.42 (d, JH–H = 2, 1 H, carbene CH),
8.60 (d, JH–H = 6, 1 H, C5H4N). 13C (acetone-d6): 13.9 (NCH2CH2CH2CH3), 20.3
(NCH2CH2CH2CH3), 33.4 (NCH2CH2CH2CH3), 51.3 (NCH2CH2CH2CH3), 94.2 (C5H5), 113.4,
118.1, 122.6, 125.8, 141.9, 158.8 (carbene CH or C5H4N). N–C(pyr) and Ni–C not observed.
Synthesis of [Im(Bu, CH2COPh)]+Br–
This compound was prepared in a similar manner to the N-methyl analogue.11 4.0!g
bromoacetophenone (20 mmol) was dissolved in THF (ca. 15 mL) and 2.6 mL N-n-
butylimidazole (20 mmol) added via syringe. There was an exothermic reaction and an
orange oil separated from the solution. Diethyl ether (ca. 10 mL) was added and the reaction
stirred overnight, after which time a white precipitate had formed with a yellow supernatant.
The solid was isolated by filtration and washed with diethyl ether until the washings were
colorless (3 x ca. 50 mL). Drying under vacuum yielded an off-white solid lump that was
broken up in the drybox. Yield: 6.1 g (94 %). Analysis calcd. For C15H19BrN2O: C, 55.7 %;
H, 5.9 %; N, 8.7 %. Found: C, 55.9 %; H, 5.7 %; N, 8.7 %. IR (KBr pellet): nC=O: 1687 cm-1.
NMR data: 1H (CDCl3): d 0.92 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3), 1.34 (sextet, JH–H  = 7, 2
H, NCH2CH2CH2CH3), 1.85 (quintet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 4.21 (t, JH–H = 7, 2 H,
NCH2CH2CH2CH3), 6.36 (s, 2 H, NCH2COC6H5), 7.42–7.46 (m, 3 H, NCH2COC6H5 and
C3H3N2), 7.59 (t, JH–H = 8, 1 H, NCH2COC6H5), 7.68 (m, 1 H, C3H3N2), 8.00 (d, JH–H = 8, 2 H,
NCH2COC6H5), 10.06 (s, 1 H, NCHN). 13C (CDCl3): d 13.3 (NCH2CH2CH2CH3), 19.3
(NCH2CH2CH2CH3), 31.9 (NCH2CH2CH2CH3), 49.9 (NCH2CH2CH2CH3), 55.7
(NCH2COC6H5), 121.1 (C3H3N2), 124.3 (C3H3N2), 128.5 (NCH2COC6H5), 129.0
(NCH2COC6H5), 133.4 (ipso-NCH2COC6H5), 134.6 (NCH2COC6H5), 137.5 (NCHN), 190.6
(NCH2COC6H5).
12
Synthesis of CpNi(Br)[Im(Bu, CH2COPh)]
THF (20 mL) was added to a mixture of 0.31 g nickelocene (1.64 mmol) and 0.53 g
[Im(Bu, CH2COPh)]+Br– (1.64 mmol) in a thick-walled glass ampoule fitted with a Teflon
stopper, and the resulting green suspension was heated at 100 °C for 4 days. After this time a
red solution had formed, with some dark insoluble residue. The solution was filtered and the
volatiles removed from the filtrate under vacuum. The red residue was washed with diethyl
ether (ca. 10 mL) and then extracted into a mixture of CH2Cl2 (5 mL) and diethyl ether (10
mL), giving a red solution with a brown oily residue. The solution was filtered and the
solvent removed under reduced pressure to give a red solid, which was dried under vacuum.
Yield: 0.38 g (52 %). Analysis calcd. For C20H23BrN2ONi: C, 53.9 %; H, 5.2 %; N, 6.3 %.
Found: C, 54.0 %; H, 5.0 %; N, 6.2 %. IR (KBr pellet): nC=O: 1699 cm-1. NMR data: 1H
(d6–acetone): d 1.02 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3), 1.51 (sextet, JH–H = 7, 2 H,
NCH2CH2CH2CH3), 2.06 (m, obscured by solvent, 2 H, NCH2CH2CH2CH3), 4.71 (m, 2 H,
NCH2CH2CH2CH3), 5.04 (s, 5 H, Cp), 6.00 (d, JH–H = 18, 1 H, NCH2COC6H5), 7.19 (d, JH–H =
18, 1 H, NCH2COC6H5), 7.32–7.35 (m, 2 H, C3H2N2), 7.65–7.76 (m, 3 H, NCH2COC6H5),
8.24–8.28 (m, 2 H, NCH2COC6H5). 13C{1H} (d6–acetone): d 10.0 (s, NCH2CH2CH2CH3), 14.0
(s, NCH2CH2CH2CH3), 33.5 (s, NCH2CH2CH2CH3), 52.1 (s, NCH2CH2CH2CH3), 58.7 (s,
NCH2COC6H5), 91.9 (s, Cp), 123.0 (s, carbene C–H), 125.3 (s carbene C–H), 128.8 (s,
NCH2COC6H5), 129.9 (s, NCH2COC6H5), 134.8 (s, NCH2COC6H5), 136.0 (s, NCH2COC6H5),
162.7 (s, Ni–C), 194.4 (s. NCH2COC6H5).
Synthesis of {Ni(acac)[Im(n-Bu, 2-Py)]}+Br–
This reaction could be performed in air. A solution of 0.54 g Ni(acac)2 (2.1 mmol)
and 0.63 g Im(n-Bu, 2-Py)+Br–.H2O (2.1 mmol) in acetone (ca. 30 mL) was stirred for 5 h,
resulting in the formation of a yellow precipitate, which was isolated by filtration, washed
with acetone (2 x ca. 10 mL) and dried under vacuum. Yield of yellow solid: 0.48 g (52 %).
Analysis calcd. for C17H22N3O2BrNi: C, 46.5 %; H, 5.1 %; N, 9.6 %. Found: C, 46.7 %; H,
4.8 %; N, 9.6 %. NMR data: 1H (CDCl3): d 0.98 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3), 1.38
(sextet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 1.78 (quintet, JH–H = 7, 2 H, NCH2CH2CH2CH3),
2.07 (s, 6 H, acac CH3), 4.17 (t, JH–H = 7, 2 H, NCH2CH2CH2CH3), 5.65 (s, 1 H, acac CH),
7.04 (s, 1 H, C3H2N2), 7.32 (m, 1 H, C5H4N), 8.18 (t, JH–H  = 8, 1 H, C5H4N), 8.27 (m, 1H,
C5H4N), 9.16 (d, JH–H  = 8, 1 H, C5H4N), 9.51 (s, 1 H, C3H2N2). 13C NMR data was not
obtained, due to insufficient solubility in all solvents tried.
Synthesis of {Im[2-Py, (CH2)3Si(OEt)3]}+I–
2.3 g (EtO)3Si(CH2)3I (6.9 mmol) was added to a solution of 1.0 g N-(2-
pyridyl)imidazole (6.9 mmol) in 30 mL toluene in a thick-walled glass ampoule fitted with a
Teflon stopper, and the cloudy tan solution was heated overnight at 120 °C. On returning to
room temperature, a dark oil separated out. The supernatant was decanted off, and the oil
washed with toluene (10 mL), pentane (2 x 20 mL), and ether (2 x 10 mL), causing a tan
solid to form, which was dried under vacuum. Yield: 0.63 g (19 %). NMR data: 1H
(d6–acetone): d 0.75 (m, 2 H, NCH2CH2CH2Si), 1.15 (t, JH–H = 7, 9 H, OCH2CH3), 2.15 (m, 2
H, NCH2CH2CH2Si), 3.79 (q, JH–H  = 7, 6 H, OCH2CH3), 4.70 (t, JH–H  = 7, 2 H,
13
NCH2CH2CH2Si), 7.65 (m, 1 H, C5H4N), 8.16 (m, 1 H, C5H4N), 8.32 (s, 1 H, C3H3N2), 8.41
(d, JH–H  = 8, 1 H, C5H4N), 8.61 (m, 2 H, C5H4N and C3H3N2), 10.73 (s, 1 H, NCHN). 13C
(d6–acetone): d 7.4 (s, NCH2CH2CH2Si), 18.4 (s, OCH2CH3), 24.7 (s, NCH2CH2CH2Si), 52.7
(s, NCH2CH2CH2Si), 58.6 (s, OCH2CH3), 115.2 (s, C5H4N), 119.7 (s, C5H4N), 124.4 (s,
C3H3N2), 125.8 (s, C5H4N), 135.5 (s, NCHN), 140.9 (s, C5H4N), 147.0 (s, Quaternary C5H4N),
149.8 (s, C3H3N2).
Synthesis of {Ni(acac)[Im(2-Py, (CH2)3Si(OEt)3)]}+I–
0.28 g {Im[2-Py, (CH2)3Si(OEt)3]}+I– (0.59 mmol) and 0.16 g Ni(acac)2 (0.62 mmol)
were dissolved in THF (ca. 10 mL), giving a yellow/green solution. After stirring a few
minutes, a yellow precipitate began to appear. The reaction was continued for 4 h, and then
the yellow solid was isolated by filtration, washed with THF (ca. 20 mL) and dried under
vacuum. Yield: 0.16 g (43 %). Analysis calcd. For C22H34IN3O5NiSi: C, 41.7 %; H, 5.4 %; N,
6.6 %. Found: C, 42.1 %; H, 5.3 %; N, 6.5 %. NMR data: 1H (CDCl3): d 0.57 (m, 2 H,
NCH2CH2CH2Si), 1.20 (t, JH–H = 7, 9 H, OCH2CH3), 1.87 (m, 2 H, NCH2CH2CH2Si), 2.05 (s,
6 H, acac), 3.79 (q, JH–H = 7, 6 H, OCH2CH3), 4.17 (t, JH–H = 7, 2 H, NCH2CH2CH2Si), 5.65
(s, 1 H, acac), 7.14 (s, 1 H, C3H3N2), 7.39 (m, 1 H, C5H4N), 8.16 (m, 1 H, C5H4N), 8.21 (m, 1
H, C5H4N), 8.69 (m, 1 H, C5H4N), 8.86 (s, 1 H, C3H3N2). 13C (CDCl3): d 7.4 (s,
NCH2CH2CH2Si), 18.2 (s, OCH2CH3), 25.1 (s, NCH2CH2CH2Si), 26.0 (s, acac) 50.4 (s,
NCH2CH2CH2Si), 58.5 (s, OCH2CH3), 102.1 (s, acac) 114.0 (s, C5H4N), 118.7 (s, C5H4N),
122.5 (s, C3H3N2), 125.9 (s, C5H4N), 143.8 (s, NCHN), 146.3 (s, C5H4N), 150.9 (s,
Quaternary C5H4N), 187.5 (s, Ni–C).
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Rh- and Pd-Based Complexes with Carbene Ligands
Discussion
There has been much recent research into the use of N-heterocyclic carbene (NHC)
complexes as catalysts, particularly as replacements for catalysts possessing phosphine
ligands.2,20,21 Synthetically, NHC-based catalysts have the advantage that imidazolium
carbene precursors can be functionalized relatively easily with additional donor groups,
which can potentially form chelating NHC ligands. We were interested in preparing
carboxylate functionalized carbene ligands, which would form C–O chelating complexes, as
analogs to the phosphine-carboxylate chelate complexes of Ni that are used as catalysts for
the oligomerization of ethylene to a-olefins in the Shell Higher Olefins Process (SHOP).22
There have been many reports of NHCs functionalized with neutral donors such as pyridine;
examples of anionic functionalized NHC ligands are less common, but have begun to appear
recently. Examples include chelating phenoxide-carbenes23-26, bis-carbene alkoxides27,28, and
a carbene-enolate.29
It was first necessary to synthesize an imidazolium substituted carboxylic acid, which
would be a precursor to a functionalized carbene ligand. It has been reported that imidazolyl
esters can be hydrolyzed to imidazolyl acetic acid simply by heating in water30,31, so it was
reasoned that analogous cationic imidazolium species might be prepared in a similar manner.
Methyl ester functionalized imidazolium salts were synthesized by treatment of an alkyl
imidazole with methyl bromoacetate, as has been reported previously11 (Scheme 5).
Hydrolysis led to formation of the corresponding imidazolium carboxylic acid. As with the
neutral imidazole-substituted species, the hydrolysis proceeded in refluxing water, but the
reaction was quite slow, requiring several days to go to completion. Addition of a catalytic
amount of acid increased the rate of reaction.
Having prepared the ligand precursor, it was then attempted to form carbene
complexes. A frequently successful method for preparing complexes of functionalized NHCs
is by deprotonation of an imidazolium salt with Ag2O, leading to a silver carbene complex,
followed by transmetallation using a halide of another metal.32 Treatment of a CH2Cl2
suspension of the imidazolium carboxylic acids [Im(R, CH2CO2H)]+Br– with Ag2O led to the
clean formation of new, CH2Cl2 soluble species. The 1H NMR of these products, however,
did not suggest a carbene complex had been formed. There was a resonance far downfield of
the others (d ca. 9.5 in CDCl3), indicative of the C2 proton of an imidazolium species. It was
believed therefore that the Ag2O had only removed the carboxylic proton, and eliminated
AgBr, to give a zwitterionic imidazolium carboxylate (Scheme 5).
Ohno has recently reported related imidazolium carboxylate zwitterions, synthesized
by a slightly different method from imidazolium ethyl esters: In this case the bromide
counterion was first ion-exchanged for OH–, followed by heating to eliminate ethanol, giving
a zwitterion.33 Furthermore, imidazolium zwitterions with carboxylate groups bound to the 2-
position (i.e. to carbon rather than nitrogen) have been prepared recently, either by treatment
of an NHC with CO234, or by the reaction of N-methylimidazole with dimethyl carbonate.35  It
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should also be noted that imidazolyl acetic acids have been in fact shown to exist as
zwitterionic imidazolium acetates in solution and the solid state.36
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Scheme 5
It was attempted to react the imidazolium zwitterions with additional Ag2O to form a
silver carbene complex. While there did appear to be some reaction, clean products could not
be isolated from this reaction. Likewise, attempts to deprotonate the imidazolium group with
sterically hindered bases such as t-BuOK or KN(SiMe3)2 followed by reaction with transition
metal salts were not successful. A potential problem with the imidazolium acetic acids is the
presence of the protons a to the carboxylate group, which would be expected to be acidic, and
may be deprotonated in preference to the imidazolium C2 proton, which would lead to
complications in trying to synthesize carbenes. It was therefore attempted to synthesize the
analogous compound with methyl groups in the a position. Such a species has also been
reported by Ohno33. An imidazolium ester was prepared by treating N-n-butylimidazole with
methyl a-bromoisobutyrate in refluxing CH3CN. The reaction has been found to work best
using 3 eq. of the imidazole.  The ester could again be hydrolyzed to give the corresponding
carboxylic acid, and a zwitterionic carboxylate could be isolated by reaction of the carboxylic
acid with 0.5 eq. of Ag2O. Treatment of the zwitterion with additional Ag2O gave an orange
complex, believed to be the silver carbene complex. The same species could be prepared
directly from the carboxylic acid by treatment with excess Ag2O (Scheme 5). The silver
carbene complex is unstable in solution; solutions rapidly start to deposit silver. Although
NMR data could be acquired, the compound could not be purified, nor X-ray quality crystals
grown, due to decomposition. So while the complex has been formulated as shown in
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Scheme 1, in reality the structure may be more complex. Silver carbene complexes have
exhibited a variety of structures.6,37,38 It has been shown that the complex of the NHC 1,3-
dimesitylimidazol-2-ylidene with AgCl crystallizes from CH2Cl2 as a monomeric
[carbene]AgCl species39. Other complexes have been found to exist as
{[carbene]2Ag}+[AgX2]– ion pairs, particularly in donor solvents. It is quite possible that the
structure of [Im(Bu, CMe2CO2)]Ag is fluxional, since the carbene carbon was not observed
by 13C-NMR, presumably due to broadening. In a static structure, a doublet should be
observed due to coupling to both 107Ag and 109Ag. Broadening of the carbene 13C resonance
has been observed previously in Ag NHC complexes and attributed to fluxionality in the
structure.28,40
Treatment of a solution of the Ag carbene complex in CH2Cl2 with a solution of
[(COD)RhCl]2 leads to immediate precipitation of AgCl, and allows a bright yellow complex
to be isolated (Scheme 6). NMR data reveals the presence of a COD ligand and the carbene
ligand, suggesting that Cl has been substituted by the carbene-carboxylate group. Complexes
of the type (COD)M[carbene]Cl have been reported previously by a related reaction
involving treatment of [(COD)MCl]2 (M = Rh, Ir) with a silver complex of a monodentate
carbene.41 Attempts to form a related Pd complex by reaction of [Im(Bu,CMe2CO2)]Ag with
1 eq. (COD)PdCl2 gave a mixture of several compounds by NMR, as did reaction with 1 eq.
PdCl2(MeCN)2. Treatment of PdCl2(MeCN)2 with 2 eq. of the Ag complex, however, gave a
product whose NMR spectrum showed only the set of resonances expected for the carbene
ligand. This species is thus presumably the bis(carbene) species [Im(Bu, CMe2CO2)]2Pd.
Scheme 6
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Experimental
Experimental Details
Reactions were performed under an inert atmosphere of Ar, using Schlenk or drybox
techniques, except where otherwise noted. N-Mesitylimidazole was synthesized as described
previously.42,43 NMR spectra were recorded a Bruker Avance 500 spectrometer. 13C NMR
peaks were assigned with the aid of HMQC spectra. Coupling constants are reported in Hz.
Synthesis of [Im(Mes, CH2CO2H)]+Br–
The methyl ester of N-mesitylimidazolium acetate was first prepared in a similar
manner to that reported for the N-methylimidazolium analogue11: 1.3 mL methyl
bromoacetate (13.7 mmol) was added via syringe to a solution of 2.34 g N-mesitylimidazole
(12.6 mmol) in THF (ca. 30 mL). On stirring, the imidazolium ester began to precipitate.
After 2 days there was a thick suspension. The THF was removed under vacuum and the
white solid residue washed with diethyl ether (2 x 20 mL) and dried. The solid was then
dissolved in deionized water (ca. 30 mL) in a thick-walled glass ampoule fitted with a Teflon
stopper, a few drops concentrated HCl (aq) added, and the solution heated at 100 °C for 2
days. After this time, the slightly brown solution was filtered to remove a small amount of
insoluble material, and the volatiles removed via rotavap. The off-white solid residue was
washed with acetone (2 x ca. 20 mL) and dried under vacuum. Yield: 2.75 g white solid (63
% based on N-mesitylimidazole). IR data (KBr pellet): nC=O: 1720 cm-1. NMR data: 1H (D2O):
d 2.05 (s, 6 H, Mes-CH3), 2.32 (s, 3 H, Mes-CH3), 5.24 (s, 2 H, NCH2CO2), 7.14 (s, 2 H,
Mes-CH), 7.57 (s, 1 H, C3H3N2), 7.78 (s, 1 H, C3H3N2), 9.01 (s, 1 H, NCHN). 13C (D2O): d
16.2 (Mes-CH3), 20.1 (Mes-CH3), 50.3 (NCH2CO2), 123.7 (C3H3N2), 124.1 (C3H3N2), 129.1
(Mes-CH), 130.6 (Mes quaternary C), 134.5 (Mes quaternary C), 137.8 (NCHN), 141.4 (Mes
quaternary C), 169.7 (NCH2CO2).
Synthesis of Im+(Mes, CH2CO2–)
CH2Cl2 (ca. 30 mL) was added to a mixture of 2.54 g [Im(Mes, CH2CO2H)]+Br– (7.8
mmol) and 0.90 g Ag2O (3.9 mmol). After stirring for 1 h, there was a slightly green
suspension. The mixture was filtered, and the solid residue extracted with more CH2Cl2 (ca.
10 mL). The filtrates were combined, the volatiles removed under vacuum, and the resulting
solid washed with pentane (ca. 10 mL) and dried under vacuum. NMR spectroscopy revealed
the presence of 0.5 eq. CH2CH2; residual amounts of CH2CH2 were invariably observed even
after extended periods under vacuum. Yield: 2.12 g of white solid (95 % assuming Im+(Mes,
CH2CO2–)(.0.5 CH2Cl2). Analysis calcd. for C14H16N2O2.0.7CH2Cl2: C, 58.1 %; H, 5.8 %; N
9.2 %. Found: C, 58.4 %; H, 5.4 %; N, 8.8 %. IR data (KBr pellet): nC=O: 1628 cm-1. NMR
data: 1H (CDCl3): d 2.06 (s, 6 H, Mes-CH3), 2.32 (s, 3 H, Mes-CH3), 5.00 (s, 2 H, NCH2CO2),
6.97 (s, 2 H, Mes-CH), 7.05 (s, 1 H, C3H3N2), 7.73 (s, 1 H, C3H3N2), 9.54 (s, 1 H, NCHN).
13C (CDCl3): d 17.5 (Mes-CH3), 21.0 (Mes-CH3), 53.4 (NCH2CO2), 121.6 (C3H3N2), 124.5
(C3H3N2), 129.7 (Mes-CH), 131.0 (Mes quaternary C), 134.5 (Mes quaternary C), 138.6
(NCHN), 140.9 (Mes quaternary C), 167.5 (NCH2CO2).
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Synthesis of [Im(Bu, CH2CO2H)]+Br–
This compound was prepared in a similar manner to the N-mesityl analogue described
above, using 2.9 mL N-n-butylimidazole (22.1 mmol) and 2.1 mL methyl bromoacetate (22.2
mmol). After hydrolysis of the ester, 4.90 g of [Im(Bu, CH2CO2H)]+Br– was isolated as an
off-white solid (84 %). Analysis calcd. for C9H15N2O2Br: C, 41.1 %; H, 5.7 %; N, 10.6 %.
Found: C, 40.5 %; H, 5.9 %; N, 10.4 %. NMR data: 1H (D2O): d 0.93 (t, JH–H = 7, 3 H,
NCH2CH2CH2CH3), 1.33 (sextet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 1.88 (quintet, JH–H = 7, 2
H, NCH2CH2CH2CH3), 4.25 (t, JH–H = 7, 2 H, NCH2CH2CH2CH3), 5.09 (s, 2 H, NCH2CO2),
7.52 (s, 1 H, C3H3N2), 7.56 (s, 1 H, C3H3N2), 8.86 (s, 1 H, NCHN).
Synthesis of Im+(Bu, CH2CO2–)
A suspension of 0.44 g Ag2O (1.9 mmol) and 1.02 g [Im(Bu, CH2CO2H)]+Br– (3.9
mmol) in CH2Cl2 (ca. 20 mL) was stirred for 30 mins, after which time the fine grey
precipitate was allowed to settle. The solution was filtered and the filtrate concentrated to ca.
10 mL. Storage in the freezer at –20 °C overnight caused a white solid to crystallize, which
was isolated by filtration and pumped dry. Yield: 0.54 g (76 %). Analysis calcd. for
C9H14N2O2: C, 59.3 %; H, 7.7 %; N, 15.4 %. Found: C, 59.2 %; H, 7.2 %; N, 14.7 %. NMR
data: 1H (CDCl3): d 0.93 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3), 1.36 (sextet, JH–H = 7, 2 H,
NCH2CH2CH2CH3), 1.84 (quintet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 4.21 (t, JH–H = 7, 2 H,
NCH2CH2CH2CH3), 4.71 (s, 2 H, NCH2CO2), 7.09 (s, 1 H, C3H3N2), 7.33 (s, 1 H, C3H3N2),
9.72 (s, 1 H, NCHN). 13C{1H} (CDCl3): d 13.4 (s, NCH2CH2CH2CH3), 19.5 (s,
NCH2CH2CH2CH3), 32.0 (s, NCH2CH2CH2CH3), 49.6 (s, NCH2CH2CH2CH3), 53.4 (s,
NCH2CO2), 119.8 (s, C3H3N2), 123.6 (s, C3H3N2), 138.2 (s, NCHN), 167.5 (s, NCH2COC6H5).
Synthesis of [Im(Bu, CMe2CO2H)]+Br–
Air sensitive conditions were not used. 5.4 mL N-n-butylimidazole (41 mmol) and
1.8 mL methyl bromoisobutyrate (14 mmol) were heated in 20 mL CH3CN at 110 °C for 3
days. After this time, the solution was concentrated to ca. 15 mL, and 80 mL ether added,
causing an orange oil to form. The oil was separated, and redissolved in ca. 10 mL acetone.
80 mL ether was added, again causing an oil to form, which was separated, and the thick,
orange oil dried under vacuum. 20 mL deionized water and ca. 0.5 mL concentrated HCl (aq)
were added, and the mixture heated at 100 °C. On heating, the oil dissolved to give an orange
solution. After heating 2 days, the volatile components were removed, giving a yellow oil.
Prolonged drying under vacuum, as well as washing with small amounts of THF, eventually
resulted in the formation of a cream-colored solid. Yield: 3.05 g (75 % overall based on
methyl bromoisobutyrate). IR data (KBr pellet): nC=O: 1737 cm-1. NMR data: 1H (D2O): d
0.92 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3), 1.32 (sextet, JH–H = 7, 2 H, NCH2CH2CH2CH3),
1.87 (quintet, 2 H, NCH2CH2CH2CH3), 1.92 (s, 6 H, NC(CH3)2), 4.24 (t, JH–H = 7, 2 H,
NCH2CH2CH2CH3), 7.57 (s, 1 H, C3H3N2), 7.68 (s, 1 H, C3H3N2), 9.03 (s, 1 H, NCHN).
13C{1H} (D2O): d 12.6 (s, NCH2CH2CH2CH3), 18.7 (s, NCH2CH2CH2CH3), 24.7 (s,
NC(CH3)2), 31.1 (s, NCH2CH2CH2CH3), 49.2 (s, NCH2CH2CH2CH3), 64.4 (s, NC(CH3)2),
121.3 (s, C3H3N2), 122.1 (s, C3H3N2), 134.9 (s, NCHN), 174.4 (s, NCH2COC6H5).
19
Synthesis of Im+(Bu, CMe2CO2–)
Air sensitive conditions were not used, except that the product was isolated and stored
in the drybox. 1.35 g Ag2O (5.8 mmol) was added to a suspension of 3.38 g [Im(Bu,
CMe2CO2H)]+Br– (11.6 mmol) in 20 mL CH2Cl2. After stirring 1 h, the resulting grey
precipitate was allowed to settle. The yellow supernatant was filtered and the solvent
removed under vacuum, to give a yellow oil, which was washed with ether (3 x 10 mL),
giving a soft white solid, which was dried under vacuum. Yield: 2.1 g (86 %). IR data (KBr
pellet): nC=O: 1627 cm-1. NMR data: 1H (CDCl3): d 0.91 (t, JH–H = 7, 3 H, NCH2CH2CH2CH3),
1.34 (sextet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 1.80 (m, obscured, 2 H, NCH2CH2CH2CH3),
1.80 (s, 6 H, NC(CH3)2), 4.30 (t, JH–H = 7, 2 H, NCH2CH2CH2CH3), 7.14 (s, 1 H, C3H3N2),
7.38 (s, 1 H, C3H3N2), 9.61 (s, 1 H, NCHN). 13C{1H} (CDCl3): d 13.4 (s, NCH2CH2CH2CH3),
19.4 (s, NCH2CH2CH2CH3), 27.1 (s, NC(CH3)2), 32.2 (s, NCH2CH2CH2CH3), 49.5 (s,
NCH2CH2CH2CH3), 67.2 (s, NC(CH3)2), 119.5 (s, C3H3N2), 120.8 (s, C3H3N2), 136.9 (s,
NCHN), 172.5 (s, NCH2COC6H5).
Synthesis of [Im(Bu, CMe2CO2)]Ag
The reaction was performed under air, but the product was worked up under Ar and
stored in the drybox. 1.23 g [Im(Bu, CMe2CO2H)]+Br– (4.2 mmol) and excess Ag2O (2.00 g,
8.6 mmol) were stirred in 40 mL CH2Cl2 overnight. The resulting black suspension was
filtered and the solvent removed from the filtrate under vacuum to give [Im(Bu,
CMe2CO2H)]Ag as an orange solid. Yield: 1.01 g (76 % based on imidazolium salt). IR data
(KBr pellet): nC=O: 1603 cm-1. NMR data: 1H (CDCl3): d 0.92 (t, JH–H = 7, 3 H,
NCH2CH2CH2CH3), 1.34 (sextet, JH–H = 7, 2 H, NCH2CH2CH2CH3), 1.80 (m, obscured, 2 H,
NCH2CH2CH2CH3), 1.84 (s, 6 H, NC(CH3)2), 4.09 (t, JH–H = 7, 2 H, NCH2CH2CH2CH3),
6.88 (s, 1 H, C3H2N2), 7.18 (s, 1 H, C3H2N2). 13C{1H} (CDCl3): d 13.7 (s, NCH2CH2CH2CH3),
19.8 (s, NCH2CH2CH2CH3), 28.6 (s, NC(CH3)2), 33.4 (s, NCH2CH2CH2CH3), 52.6 (s,
NCH2CH2CH2CH3), 66.0 (s, NC(CH3)2), 118.5 (s, carbene C–H), 118.6 (s, carbene C–H),
177.3 (s, NCH2COC6H5), (Ag–C not observed).
Synthesis of (COD)Rh[Im(Bu, CMe2CO2)]
A solution of 0.25 g [(COD)RhCl]2 (1.0 mmol Rh) in ca. 3 mL CH2Cl2 was added to a
solution of 0.33 g [Im(Bu, CMe2CO2)]Ag (1.0 mmol) in 20 mL CH2Cl2. There was
immediate formation of a tan precipitate, which was allowed to settle. The yellow
supernatant was filtered and the solvent removed under vacuum. The resulting bubbly solid
was washed with ether (ca. 5 mL) and dried under vacuum, yielding 0.36 g of a bright yellow
powder (85 %). IR data (KBr pellet): nC=O: 1616 cm-1. NMR data: 1H (CDCl3): d 0.99 (t, JH–H
= 8, 3 H, NCH2CH2CH2CH3), 1.37 (sextet, JH–H = 8, 2 H, NCH2CH2CH2CH3), 1.79 (quintet,
JH–H = 8, 2 H, NCH2CH2CH2CH3), 1.93 (m, 4 H, COD), 2.27 (s, 6 H, NC(CH3)2), 2.39 (m, 4
H, COD), 3.83 (m, 2 H, COD), 3.91 (t, JH–H = 8, 2 H, NCH2CH2CH2CH3), 4.78 (m, 2 H,
COD), 6.69 (d, JH–H = 2, 1 H, C3H2N2), 6.98 (d, JH–H = 2, 1 H, C3H2N2). 13C{1H} (CDCl3): d
13.7 (s, NCH2CH2CH2CH3), 20.0 (s, NCH2CH2CH2CH3), 28.2 (s, COD), 29.4 (s, NC(CH3)2),
33.0 (s, COD), 34.2 (s, NCH2CH2CH2CH3), 50.4 (s, NCH2CH2CH2CH3), 64.8 (s, NC(CH3)2),
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66.7 (d, JRh–C = 14), 97.0 (d, JRh–C = 8), 118.2 (s, carbene C–H), 119.4 (s, carbene C–H), 174.7
(s, NCH2COC6H5), ca. 174 (obscured, Rh–C).
Synthesis of [Im(Bu, CMe2CO2)]2Pd
A solution of 0.23 g PdCl2(MeCN)2 (0.89 mmol) in 20 mL CH2Cl2 was added to a
solution of 0.56 g [Im(Bu, CMe2CO2)]Ag (1.77 mmol) in 20 mL CH2Cl2. A grey suspension
formed immediately. The reaction was stirred for 2 h, and then the grey solid allowed to
settle. The pale yellow supernatant was filtered and the solvent removed under vacuum, to
give 0.40 g [Im(Bu, CMe2CO2)]2Pd as a light yellow solid (86 %). NMR data: 1H (CDCl3):
d 0.94 (t, JH–H = 7, 6 H, NCH2CH2CH2CH3), 1.40 (sextet, JH–H = 7, 4 H, NCH2CH2CH2CH3),
1.88 (quintet, JH–H = 7, 4 H, NCH2CH2CH2CH3), 2.14 (s, 12 H, NC(CH3)2), 4.26 (t, JH–H = 7, 4
H, NCH2CH2CH2CH3), 6.82 (d, JH–H = 2, 2 H, C3H2N2), 7.01 (d, JH–H = 2, 2 H, C3H2N2).
13C{1H} (CDCl3): d 13.8 (s, NCH2CH2CH2CH3), 20.0 (s, NCH2CH2CH2CH3), 28.7 (s,
NC(CH3)2), 34.0 (s, NCH2CH2CH2CH3), 49.3 (s, NCH2CH2CH2CH3), 64.1 (s, NC(CH3)2),
117.7 (s, carbene C–H), 119.8 (s, carbene C–H), 162.8 (s, Pd–C), 174.8 (s, NCH2OC6H5).
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X-ray Crystal Structure Thermal Ellipsoid Plots
Figure 2.  X-ray structure of {CpNi-h2-[Im(Bu,2-Py)]}+ BF4-
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Figure 3.  X-ray structure of CpNi[Im(Bu,CH2COPh)]Br
Figure 4.  X-ray structure of {Ni(acac)[Im(2-Py,(CH2)3Si(OEt)3)]}+ I–
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